U.S. market Closed. Opens in 21 hours 12 minutes

ATAI | Atai Life Sciences N.V. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 1.4600 - 1.5700
52 Week Range 1.0300 - 2.8500
Beta 1.21
Implied Volatility 206.79%
IV Rank 35.52%
Day's Volume 1,185,756
Average Volume 2,886,366
Shares Outstanding 198,306,000
Market Cap 291,509,820
Sector Healthcare
Industry Biotechnology
IPO Date 2021-06-18
Valuation
Profitability
Growth
Health
P/E Ratio -1.58
Forward P/E Ratio -2.01
EPS -0.93
1YR Price Target 11.00
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 83
Country Germany
Website ATAI
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
*Chart delayed
Analyzing fundamentals for ATAI we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see ATAI Fundamentals page.

Watching at ATAI technicals we can see that long-term trend is bullish, while middle-term trend is bearish, as well as bearish short-term trend. More technicals details can be found on ATAI Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙